Evaluation of Pembrolizumab and Ataluren in Metastatic pMMR/dMMR Colorectal Adenocarcinomas and Metastatic dMMR Endometrial Carcinoma
- Trial ID
- 2023-509457-31-00
- Sponsor
- Amsterdam UMC Stichting
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of the ATAPEMBRO study is to evaluate the efficacy of combining **Pembrolizumab** with **Ataluren** in patients diagnosed with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma. This study is clinically relevant as it aims to explore potential therapeutic benefits in treating these advanced malignancies, which are characterized by poor prognosis and limited treatment options. The investigation focuses on the potential synergistic effects of the drug combination, which could lead to improved patient outcomes in these challenging cancer types.
Participants
The clinical trial involves participants diagnosed with **metastatic colon cancer** or advanced cancer of the colon. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The trial aims to gather data from a diverse group of individuals affected by these conditions, although further details on the selection process remain unspecified.
Plans and Procedures
The clinical trial is designed to evaluate the efficacy and safety of **pembrolizumab** combined with ataluren in patients diagnosed with metastatic colon cancer or advanced cancer of the colon. The study follows a randomized, double-blind, controlled trial design, ensuring that neither the participants nor the investigators are aware of the treatment assignments, thus minimizing bias. The trial commenced on January 1, 2019, and is projected to conclude by December 1, 2025, encompassing a total duration of approximately six years.
Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This visit is crucial for determining the suitability of participants for the trial based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess treatment efficacy, and record any adverse events. The frequency and number of follow-up visits are determined by the study protocol and are essential for collecting consistent data throughout the trial period. The end-of-study visit marks the final assessment of the participants, where comprehensive evaluations are conducted to gather concluding data on the treatment's impact.
The expected length of participant involvement in the trial is contingent upon the individual's response to the treatment and adherence to the study protocol. Participants may be withdrawn from the study prematurely if they experience significant adverse effects, fail to comply with the study requirements, or if the investigator deems it necessary for the participant's safety. The trial's methodology and structured visit schedule are designed to ensure the collection of robust and reliable data, contributing to the understanding of the treatment's potential benefits and risks in the specified patient population.
Treatment
In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of this data precludes a comprehensive description of the treatments used in this clinical trial.
Efficacy
The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to conclude by December 1, 2025, with recruitment having commenced on January 1, 2019. The trial is categorized under phase 9, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
The Netherlands | Not Recruiting | 01 Jan 2019 | — |
Netherlands | — | — | 47 |

